<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775579</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MERO-101</org_study_id>
    <nct_id>NCT01775579</nct_id>
  </id_info>
  <brief_title>Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium</brief_title>
  <official_title>Randomized, Open Label, Multiple-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We investigate the potential pharmacokinetic drug-drug interaction between metformin extended
      release and rosuvastatin in healthy male volunteers who receive metformin extended release
      alone, rosuvastatin alone, and both together in a 3 period repeatedly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metformin, Rosuvastatin Cmaxss</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>metformin, rosuvastatin AUC</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metformin, Rosuvastatin tmaxss</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, Rosuvastatin t1/2</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, Rosuvastatin C min,ss</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, Rosuvastatin CL/Fss</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin, Rosuvastatin Vd/Fss</measure>
    <time_frame>0h(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 9, 10, 12, 14, 24, 48 h of each period (total 16)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Crestor tablet 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crestor tablet 20 mg single---&gt;wash out----&gt;Glucophage SR tablet 750 mg single----&gt;washout---&gt;Glucophage SR tablet 750 mg, Crestor tablet 20 mg both</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage SR tablet 750 mg and Crestor tablet 20 mg both</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucophage SR tablet 750 mg, Crestor tablet 20 mg both---&gt;wash out----&gt;Glucophage SR tablet 750 mg single------&gt;washout---&gt;Crestor tablet 20 mg single</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage SR tablet 750 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucophage SR tablet 750 mg single ---&gt;wash out----&gt;Crestor tablet 20 mg single----&gt;washout---&gt;Glucophage SR tablet 750 mg, Crestor tablet 20 mg both</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage SR tablet 750 mg, Crestor tablet 20 mg</intervention_name>
    <arm_group_label>Crestor tablet 20 mg</arm_group_label>
    <arm_group_label>Glucophage SR tablet 750 mg and Crestor tablet 20 mg both</arm_group_label>
    <arm_group_label>Glucophage SR tablet 750 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, age 20 to 55 years.

          2. The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 27 kg/m2

          3. Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in kidney, liver, cardiovascular system, respiratory system,
             endocrine system, or neuropsychiatric system.

          2. Glomerular filtration rate is under 60ml/min which is calculated by serum creatinine
             value.

          3. Liver enzyme (AST, ALT) level exceeds one and a half times more than maximum normal
             range.

          4. Systolic blood pressure &lt;90mmHg or Diastolic blood pressure &lt; 60 mmHg, systolic blood
             pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg(Sitting blood pressure)
             during the screening procedure.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samgsung Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>August 22, 2013</last_update_submitted>
  <last_update_submitted_qc>August 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

